m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05078
 [1]
Non-coding RNA CircDDIT4 ELAVL1  lncRNA       miRNA   circRNA Direct Inhibition m6A modification ANO7 ANO7 ELAVL1 : m6A sites
m6A Modification:
m6A Regulator ELAV-like protein 1 (ELAVL1) READER
 Regulator Info 
m6A Target Anoctamin-7 (ANO7)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_DDIT4 circRNA View Details
Regulated Target ELAV-like protein 1 (HuR/ELAVL1) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary m6A-Mediated Biogenesis of Circ_DDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR.By competitively binding to ELAV-like RNA binding protein 1 (ELAVL1/HuR) through its 3'-UTR, circDDIT4 acts as a protein sponge to decrease the expression of prostate cancer-overexpressed Anoctamin-7 (ANO7).
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
In-vitro Model
 WPMY-1 Normal Homo sapiens CVCL_3814
LNCaP Prostate carcinoma Homo sapiens CVCL_0395
22Rv1 Prostate carcinoma Homo sapiens CVCL_1045
DU145 Prostate carcinoma Homo sapiens CVCL_0105
LNCaP C4-2B Prostate carcinoma Homo sapiens CVCL_4784
PC-3 Prostate carcinoma Homo sapiens CVCL_0035
LNCaP C4-2 Prostate carcinoma Homo sapiens CVCL_4782
HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model Ten mice were randomly divided into two groups, and C4-2-pZXE-circDDIT4 or C4-2-pZXE-NC cell suspension was concentrated to 5 × 106 cells/100 μ L PBS and then injected into the flanks of the nude mice. After 20 days, the mice were euthanized, and the xenograft tumors were harvested, weighed, and photographed.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C82: Prostate cancer 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name CC-94676 Phase 1 [2]
External Link
TTD: DNY63Z
References
Ref 1 m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR. Mol Cancer Res. 2023 Dec 1;21(12):1342-1355. doi: 10.1158/1541-7786.MCR-22-0271.
Ref 2 ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.